Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 163

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 163
---
 |

| ● | no                                                         
 evidence of T cell exhaustion despite repeated challenges; |

| ● | no                                           
 observed off-target or off-tumor toxicities; |

| ● | expression                                                                              
 and maintenance of diverse T cell populations, including naïve and memory cells, likely 
 indicative of response persistence and durability; and                                  |

| ● | well                                          
 defined and scalable manufacturing protocols. |

We have designed CER-1236
to align with components included in the current generation of conventional CAR-T configurations by fusing the external domain of TIM-4,
a phagocytic receptor, with intracellular signaling domains from T cells and innate immune cells. TIM-4 harbors endogenous phagocytic
capacity through its binding to the pro-phagocytic “eat-me” signal TIM-4-L. CER-1236’s intracellular signaling
domains, including TLR2, CD28 and CD3ξ motifs, are designed to augment both TIM-4 mediated phagocytosis and cytotoxic T cell function.
Another similarity between conventional CAR-T therapeutic formats and our CER-T design is the delivery vehicle used in transduction.
As is found in many approved CAR-T therapies, our CER-T technology also employs a lentiviral vector to facilitate gene delivery to patient-derived
T cells. A schematic of the structural elements of CER-1236 is presented below.

Schematic of CER-1236

Abbreviations: TIM-4 = ectodomain
of the T cell immunoglobulin mucin domain protein 4; TLR2 = toll-like receptor 2.

CER-1236 employs an innovative mechanism of action

CER-1236 is an autologous
T cell therapy candidate designed to target TIM-4-L through the external domain of the prophagocytic receptor TIM-4 protein. This therapeutic
construct was developed to combine adaptive T cell killing activity with phagocytic clearance and antigen presentation activity to create
T cells with enhanced cancer immunotherapy capabilities. The approach builds on the early success of adoptive T cell transfer, which
has demonstrated the ability of T cells to proliferate, traffic, and circulate within both primary and metastatic tumors.

By enhancing phagocytic
clearance and antigen presentation activity and integrating them into T cells, we believe CER-T cells offer the potential for more effective
elimination of cancer cells. The industry’s decades-long experience with engineered T cell use provides a solid foundation for